The article deals with the issues of the rational approach for attracting investments in the process of commercialization of R&D results in the field of biomedical science by Ukrainian scientists. Some differences between business angels, venture capital (VC), and corporate venture capital (CVC) funds have been investigated. It has been found that engagement with CVC can have several important advantages over other types of investors. Maximizing profits is not the most important task for CVC. This leads to the fact that innovators can expect better financial results when evaluating a startup by CVC comparing with a conventional VC. Corporate venture fund experts are well aware of the situation in the profile market and are able to evaluate professionally the proposed technology immediately, despite possible mistakes in the pitch presentation or business plan. An analysis of all three investor groups (business angels, VCs and CVCs) showed that CVC are equally important to Ukrainian innovators, because unlike the first two groups of potential investors, they may consider the proposed technology despite the lack of professional business managers, or successful serial entrepreneurs in a team that often happens in Ukraine. In this context, obtaining professional advice, assistance in the formation of a company team, or potential licensing are extremely important. Also, quite relevant is the increased likelihood of a better financial result when assessing by CVC and the fact that the CVC brand of a large multinational company will increase the bargaining position with other funds in subsequent rounds of investment.